Full-Time

Director – Finance and Strategic Modeling

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$210k - $253kAnnually

Senior, Expert

San Carlos, CA, USA

Position is based out of headquarters in Redwood City, CA.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Requirements
  • Bachelor’s degree and 10+ years of relevant experience in finance, banking, and/or consulting.
  • Advanced excel-based modelling experience.
  • Strong analytical and strategic thinking skills.
  • Excellent written and verbal communication skills.
  • Ability to lead teams and collaborate cross-functionally.
  • Initiative-taking and able to work independently.
  • Resourceful, motivated, and able to identify potential issues or problems and find solutions.
Responsibilities
  • Create and maintain financial models (P&L, Valuation, NPV, DCF) that help guide near and long-term portfolio planning and decision making.
  • Provide finance support and develop financial models to assist in business development and corporate strategy efforts.
  • Assist in maintenance and update of the long-range financial model.
  • Conduct scenario and sensitivity analyses
  • Support and provide financial insights for portfolio planning and prioritization.
  • Deliver clear, articulate analyses and insights to inform decisions for single assets and larger portfolio.
  • Effectively partner with multiple functions to align on key assumptions, including commercial organization for revenue projections and program management for probability of technical and regulatory success (PTRS)
  • Ad-hoc financial analysis support

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?